Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a potent, cell-permeable inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with an IC₅₀ of approximately 140 nM for ROCK1 and Ki of 300 nM for ROCK2, exhibiting >200-fold selectivity over other kinases (APExBIO). Inhibition of ROCK by Y-27632 disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and interferes with cytokinesis (de Hoyos-Vega et al., 2023). The compound is highly soluble and stable under standard laboratory conditions, supporting its use in various cell and tissue models. Y-27632 is widely applied in stem cell, cancer, and cytoskeletal research, and is a benchmark tool for dissecting Rho/ROCK signaling (see comparative review).

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that regulate cytoskeletal dynamics, cell motility, and proliferation. In the gastrointestinal tract and other epithelia, ROCK signaling mediates cellular contractility and barrier function (de Hoyos-Vega et al., 2023). Dysregulation of the Rho/ROCK pathway has been implicated in cancer cell invasion, metastasis, and abnormal tissue remodeling. Pharmacological inhibition of ROCK with Y-27632 dihydrochloride enables precise modulation of these pathways, facilitating studies on stem cell viability, tumor progression, and neuroepithelial communication. The compound's selectivity is critical for isolating ROCK-dependent effects from those mediated by other kinases, such as PKC or MLCK.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds to the catalytic domain of ROCK1 and ROCK2, competitively inhibiting ATP binding. This blockage disrupts phosphorylation of downstream substrates including myosin light chain (MLC) and LIM kinase. The result is inhibition of actin stress fiber formation, reduced cell contractility, and modulation of cell cycle checkpoints. The compound has an IC₅₀ of ~140 nM for ROCK1 and a Ki of 300 nM for ROCK2, remaining >200-fold less active against related kinases such as protein kinase C (PKC), cAMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and p21-activated kinase (PAK) (APExBIO).

By disrupting Rho/ROCK-driven cytoskeletal remodeling, Y-27632 impedes formation of stress fibers and focal adhesions, key determinants of cellular morphology and migration. It also delays G1/S cell cycle progression and inhibits cytokinesis, thereby affecting cell proliferation and survival in both normal and pathological contexts.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 activity with an IC₅₀ of 140 nM in vitro, demonstrating nanomolar potency (APExBIO).
• ROCK2 inhibition occurs with a Ki of 300 nM, ensuring high selectivity for Rho/ROCK signaling in cell-based assays (APExBIO).
• Y-27632 blocks Rho-mediated formation of cellular stress fibers in diverse cell types, including intestinal epithelial and smooth muscle cells (de Hoyos-Vega et al., 2023).
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a dose-dependent manner (see benchmarking facts).
• In vivo, Y-27632 suppresses tumor invasion and metastasis in mouse cancer models (de Hoyos-Vega et al., 2023).
• Y-27632 is highly soluble: ≥111.2 mg/mL (DMSO), ≥17.57 mg/mL (ethanol), and ≥52.9 mg/mL (water; warming at 37°C or sonication recommended) (APExBIO).
• Stock solutions are stable at <-20°C for several months; long-term solution storage is not advised (APExBIO).

This article extends the mechanistic depth found in Strategic Modulation of the Rho/ROCK Pathway by detailing solubility and storage benchmarks, and updates the applications scope beyond cytoskeletal remodeling described in Unlocking Neuroepigenetic and Cancer Mechanisms. For advanced evidence on tight junction regulation, see this integrative overview.

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is broadly applicable in studies of:

• Cytoskeletal organization and actin dynamics (de Hoyos-Vega et al., 2023).
• Stem cell expansion and maintenance, especially human pluripotent stem cells (hPSCs) (benchmarking facts).
• Cell proliferation and viability assays, including prostatic and intestinal smooth muscle cells.
• Tumor invasion, metastasis, and cancer model systems.
• Neuroepithelial and enteric nervous system co-culture models (de Hoyos-Vega et al., 2023).

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit all kinases; it is >200-fold selective for ROCK1/2 over PKC, PKA, MLCK, and PAK (APExBIO).
• The compound does not prevent apoptosis in all cell types; its protective effect is context-dependent (see clarification).
• Y-27632 is not suitable for long-term solution storage; degradation may occur above -20°C or over extended periods.
• It does not address all aspects of cancer progression—effects are primarily due to cytoskeletal and migration pathways, not direct anti-proliferative activity in all contexts.
• Y-27632 is not a therapeutic drug; it is for research use only (RUO).

Workflow Integration & Parameters

For optimal results, Y-27632 dihydrochloride should be dissolved at concentrations up to 111.2 mg/mL in DMSO, 17.57 mg/mL in ethanol, or 52.9 mg/mL in water. Warming to 37°C or using an ultrasonic bath can accelerate dissolution. Stock solutions should be aliquoted and stored at <-20°C (desiccated, 4°C for solids) and protected from repeated freeze-thaw cycles. In cell culture, concentrations from 1–20 μM are typical, but optimal dosing should be empirically determined for each application. For stem cell passaging, 10 μM is commonly used to enhance viability. In cancer invasion assays, titration is required to balance cytoskeletal modulation with cell toxicity (APExBIO).

When integrating with co-culture systems (e.g., neuroepithelial models), researchers should adapt media and substrate conditions to support both cell types, as outlined in recent microfluidics studies. For additional strategic guidance, this review contrasts compartment-specific contractility findings.

Conclusion & Outlook

Y-27632 dihydrochloride, available from APExBIO as SKU A3008, is a benchmark ROCK inhibitor for cytoskeletal, stem cell, and cancer research. Its nanomolar potency and high kinase selectivity enable precise modulation of Rho/ROCK signaling in both basic and translational studies. While not a therapeutic, its impact on workflow reproducibility and experimental scope is substantial. Ongoing research continues to expand its utility in epithelial, neuronal, and tumor microenvironment models, supporting next-generation discoveries in cell biology and regenerative medicine.